OCGN
Ocugen Inc
NASDAQ: OCGN · HEALTHCARE · BIOTECHNOLOGY
$1.48
+5.38% today
Updated 2026-06-04
Market cap
$419.77M
P/E ratio
—
P/S ratio
94.01x
EPS (TTM)
$-0.24
Dividend yield
—
52W range
$1 – $3
Volume
6.9M
WallStSmart proprietary scores
19
out of 100
Grade: F
Strong Sell
Investment rating
6.0
Growth
B5.0
Quality
C+2.5
Profitability
F5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$11.43
+672.30%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-21.80M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.49M | $6.04M | $4.05M | $4.41M | $4.46M |
| Net income | $-77.83M | $-63.08M | $-54.05M | $-67.85M | $-19.18M |
| EPS | — | — | — | — | $-0.24 |
| Free cash flow | $-64.54M | $-72.53M | $-45.53M | $-57.15M | $-21.80M |
| Profit margin | -3,128.38% | -1,045.03% | -1,333.02% | -1,537.41% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | ZHANG, JUNGE | Sale | 112,205 | — |
| 2026-04-01 | ZHANG, JUNGE | Sale | 66,929 | — |
| 2026-04-01 | ZHANG, JUNGE | Sale | 15,000 | — |
Peer comparison
Smart narrative
Ocugen Inc trades at $1.48. Our Smart Value Score of 19/100 indicates the stock is weak. TTM revenue stands at $4.46M.
Frequently asked questions
What is Ocugen Inc's stock price?
Ocugen Inc (OCGN) trades at $1.48, on a P/S of 94.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Ocugen Inc overvalued?
Ocugen Inc carries a Smart Value Score of 19/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Ocugen Inc (OCGN)?
The 12-month analyst consensus target is $11.43, about 672.3% above the current $1.48. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Ocugen Inc's revenue?
Ocugen Inc's trailing twelve-month revenue is $4.46M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio94.01x
ROE-660.00%
Beta2.21
50D MA$1.60
200D MA$1.52
Shares out0.34B
Float0.32B
Short ratio—
Avg volume6.9M
Performance
1 week+0.00%
1 month-6.16%
3 months-44.76%
YTD+1.48%
1 year—
3 years—
5 years—